Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Study Identifier:
C07-003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
- Multiple Myeloma
Study Drug
- Drug: Samalizumab
Date
Jun 2008 - Dec 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
- Multiple Myeloma
Study Drug
- Drug: Samalizumab
Date
Jun 2008 - Dec 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to study how samalizumab may help the immune system fight tumors that express CD200.
Trial Locations
Location
Status
Location
Tucson, Arizona, United States, 85719
Status
N/A
Location
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Morristown, New Jersey, United States, 07962
Status
N/A
Location
Durham, North Carolina, United States, 27710
Status
N/A